We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

115 hedge funds and large institutions have $710M invested in Celldex Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $22.4M | Put options by funds: $16.3M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

10% more capital invested

Capital invested by funds: $645M → $710M (+$64.5M)

3% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 38

5.84% less ownership

Funds ownership: 93.04% → 87.2% (-5.8%)

12% less funds holding

Funds holding: 130 → 115 (-15)

45% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 33

Holders
115
Holders Change
-15
Holders Change %
-11.54%
% of All Funds
2.02%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
18
Increased
39
Reduced
38
Closed
33
Calls
$22.4M
Puts
$16.3M
Net Calls
+$6.17M
Net Calls Change
+$2.92M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$41.2M
2
RG
Redmile Group
California
+$15.5M
3
RI
RTW Investments
New York
+$11.2M
4
VA
VR Adviser
New York
+$10.1M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.76M

Top Sellers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
-$28.9M
2
IC
Ikarian Capital
Texas
-$17.7M
3
BC
Boxer Capital
California
-$17.5M
4
ACP
Acuta Capital Partners
California
-$14M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$6.96M +$7.76M +337,899 +33,789,900%
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$6.84M +$899K +39,162 +13%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$6.25M -$105K -4,563 -1%
Axa
29
Axa
France
$6.13M +$6.6M +287,283 +2,736%
CS
30
Candriam SCA
Luxembourg
$5.79M – – –
Invesco
31
Invesco
Georgia
$5.37M +$5.98M +260,495 New
GTC
32
Ghost Tree Capital
New York
$5.15M +$5.74M +250,000 New
SFM
33
Sphera Funds Management
Israel
$4.54M -$8.65M -376,878 -63%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$4.33M -$4.39M -191,300 -48%
TLP
35
Tri Locum Partners
New York
$4.05M +$4.52M +196,672 New
Citigroup
36
Citigroup
New York
$3.57M +$3.16M +137,687 +387%
PVI
37
Pura Vida Investments
New York
$3.37M +$3.76M +163,615 New
DP
38
DSAM Partners
United Kingdom
$2.8M -$783K -34,093 -20%
ECM
39
ExodusPoint Capital Management
New York
$2.79M -$805K -35,039 -21%
Verition Fund Management
40
Verition Fund Management
Connecticut
$2.74M -$975K -42,475 -24%
AAA
41
Affinity Asset Advisors
New York
$2.68M +$1.26M +55,000 +73%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$2.49M +$2.19M +95,268 +369%
HF
43
HRT Financial
New York
$2.27M +$216K +9,387 +9%
Northern Trust
44
Northern Trust
Illinois
$2.21M +$281K +12,217 +13%
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.86M +$43.6K +1,900 +2%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.74M +$231K +10,068 +14%
Group One Trading
47
Group One Trading
Illinois
$1.7M +$1.34M +58,478 +242%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$1.62M -$205K -8,909 -10%
MCP
49
Mirador Capital Partners
California
$1.56M +$1.12M +48,927 +183%
BFM
50
Boothbay Fund Management
New York
$1.53M -$2.42M -105,471 -59%
1
2
3 4 5

CLDX Hedge Fund Activity: Q1 2021 in Review

115 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2021, worth a combined $710M — up 10% from $645M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of CLDX and 18 opened new positions — a net loss of 15 holders — while 38 trimmed existing stakes and 39 added.

The largest buyer was Wellington Management Group, adding an estimated $41.2M. The largest seller was Marshall Wace North America, cutting an estimated $28.9M.

  • 115 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2021, down from 130 in Q4 2020.
  • Funds reported $710M of Celldex Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
  • 18 funds opened new Celldex Therapeutics positions in Q1 2021 and 33 closed out, a net change of -15 holders.
  • The largest Celldex Therapeutics buyer in Q1 2021 was Wellington Management Group, an estimated $41.2M added.
  • The largest Celldex Therapeutics seller in Q1 2021 was Marshall Wace North America, an estimated $28.9M sold.

Based on aggregated 13F filings for Q1 2021.